A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (11697)
- Bioengineering (8714)
- Bioinformatics (29116)
- Biophysics (14924)
- Cancer Biology (12047)
- Cell Biology (17347)
- Clinical Trials (138)
- Developmental Biology (9405)
- Ecology (14136)
- Epidemiology (2067)
- Evolutionary Biology (18260)
- Genetics (12214)
- Genomics (16758)
- Immunology (11838)
- Microbiology (27986)
- Molecular Biology (11544)
- Neuroscience (60776)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3228)
- Physiology (4936)
- Plant Biology (10381)
- Synthetic Biology (2876)
- Systems Biology (7331)
- Zoology (1642)